Ladenburg Thalmann Financial Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,000	Closed	-$5K	–	5169
2018 Q2	$5K	Hold	2,000	–	–	﹤0.01%	4571
2018 Q1	$5K	Hold	2,000	–	–	﹤0.01%	4571
2017 Q4	$8K	Hold	2,000	–	–	﹤0.01%	4297
2017 Q3	$5K	Hold	2,000	–	–	﹤0.01%	4384
2017 Q2	$6K	Hold	2,000	–	–	﹤0.01%	4241
2017 Q1	$4K	Hold	2,000	–	–	﹤0.01%	4366
2016 Q4	$2K	Hold	2,000	–	–	﹤0.01%	4514
2016 Q3	$2K	Hold	2,000	–	–	﹤0.01%	4454
2016 Q2	$1K	Hold	2,000	–	–	﹤0.01%	4539
2016 Q1	$2K	Hold	2,000	–	–	﹤0.01%	4369
2015 Q4	$5K	Hold	2,000	–	–	﹤0.01%	4031
2015 Q3	$6K	Hold	2,000	–	–	﹤0.01%	3818
2015 Q2	$8K	Sell	2,000 -1,000	-33%	-$3.99K	﹤0.01%	3815
2015 Q1	$13K	Buy	+3,000	New	+$10.8K	﹤0.01%	3444
2014 Q3	–	Sell	-5,500	Closed	-$14K	–	3931
2014 Q2	$14K	Hold	5,500	–	–	﹤0.01%	2887
2014 Q1	$12K	Buy	+5,500	New	+$11.5K	﹤0.01%	2855
2013 Q4	–	Sell	-5,500	Closed	-$17K	–	3745
2013 Q3	$17K	Buy	+5,500	New	+$9.25K	﹤0.01%	2550

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CPRX Position: Q3 2018 in Review

Ladenburg Thalmann Financial Services sold out of Catalyst Pharmaceutical (CPRX) in Q3 2018, closing a stake of 2,000 shares — an estimated $5K sold.

Ladenburg Thalmann Financial Services first reported a position in CPRX in Q3 2013 and held it in 17 quarters. The position peaked at $17K in Q3 2013. 97 funds tracked by Wall St. Rank hold CPRX as of Q3 2018.

Ladenburg Thalmann Financial Services reported no remaining Catalyst Pharmaceutical position as of Q3 2018 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 2,000 Catalyst Pharmaceutical shares in Q3 2018, an estimated $5K.
Ladenburg Thalmann Financial Services first reported a position in Catalyst Pharmaceutical in Q3 2013 and held it in 17 quarters.
Ladenburg Thalmann Financial Services's Catalyst Pharmaceutical position peaked at $17K in Q3 2013.
97 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2018, filed 14 Nov 2018.